Pulmonary Drug Delivery Systems: Technologies and Global Markets

  • ID: 4522145
  • Report
  • Region: Global
  • 121 pages
  • BCC Research
15 % OFF
until Dec 31st 2018
1 of 6

FEATURED COMPANIES

  • 3M Pharmaceuticals, Inc.
  • Boehringer Ingelheim Gmbh
  • Glaxosmithkline Plc
  • Mylan N.V.
  • Omron Corporation
  • Pulmatrix, Inc.
  • MORE
Report Scope:

This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, research and development pipeline, and blockbuster drugs.

In the report the regulatory scenario of pulmonary drug delivery systems is discussed for device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are analyzed in the Pipeline Analysis section.

A discussion of the major players is included in the Competitive Landscape section. The Competitive Landscape section provides trends in product launch, collaborations, mergers and acquisitions, and other agreements. Company profiles of major players operating in the pulmonary drug delivery systems market are included with an overview, key product offerings, financials, strategies, strength, weakness, opportunities and threats (SWOT) and developments. The report will be useful for analysis of the leading products and will enable readers to recognize growing brands, key device types and leading manufacturing companies with significant market share.

Report Includes:
  • 74 tables
  • A detailed overview and analysis of the global markets for pulmonary drug delivery systems
  • Analyses of global market trends, with data from 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • Assessments of pulmonary drug delivery systems by regions, delivery systems/types, and disease areas
  • A look at the regulatory environment, which has been a driving force in the healthcare industry
  • Reviews of key developments, novel product innovations, and recent strategic industry activities of major players across various product categories
  • Detailed profiles of major vendors in the market, including 3M Pharmaceuticals Inc., AstraZeneca plc, Cipla Inc., GlaxoSmithKline plc and Lupin Ltd
Membership Price:

Contact us for membership pricing.
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • 3M Pharmaceuticals, Inc.
  • Boehringer Ingelheim Gmbh
  • Glaxosmithkline Plc
  • Mylan N.V.
  • Omron Corporation
  • Pulmatrix, Inc.
  • MORE
1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
Related Reports

2 Summary and Highlights

3 Market Dynamics and Technology Background
Market Definition and Overview
Mechanism of Action
Advantages
Limitations/Challenges
Pulmonary Conditions and Therapies
Introduction to the Respiratory System
Market Driving Factors and Trends
Improved Patient Compliance and Ease of Use Leading to Adoption of Inhalation Products
Cost Pressure on Countries Imposing Adoption of Cost-Effective Devices
Rising Incidence of Asthma and COPD in Developing and Developed Regions
Market Restraints
Competition from Generics on the Rise Due to Patent Expiry of Blockbuster Products
Market Opportunities
Introduction of Smart Nebulizers
Regulation and Legislation
United States

4 Market Breakdown by Pulmonary Drug Delivery Systems
Overview of Inhalation Techniques
Leading Respiratory Products
Dry Powder Inhalers (DPIs)
Overview
Marketed Products
Market Size and Forecast
Metered Dose Inhalers (MDI's)
Overview
Marketed Products
Market Size and Forecast
Nebulizers
Overview
Marketed Products Overview by Manufacturer)
Market Size and Forecast

5 Pulmonary Drug Delivery Drugs in Use
Therapeutic Agents Administered via Inhalation
Steroids
Bronchodilators

6 Market Breakdown by Disease Area
Introduction
Asthma
Asthma Attack
Asthma and Obesity
Mortality
Disease Classification
Diagnosis
Treatment and Therapies
Market Size and Forecasts
Chronic Obstructive Pulmonary Disease (COPD)
Diagnosis
Treatment and Therapies
Market Size and Forecasts
Other Diseases
Market Size and Forecast

7 Market Breakdown by Region
North America
U.S.A.
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
Rest of Asia Pacific
Middle East and Africa
South America

8 Competitive Landscape and Key Developments
Leading Players and Market Structure Analysis
Patent Analysis
List of Key Patents
Pipeline Analysis
Fasenra (benralizumab) Approved for Severe Eosinophilic Asthma in U.S., Japan and European Countries
GOLDEN Clinical Study Analysis of SUN-101/ eFlow (Glycopyrrolate) For the Treatment of COPD
Key Developments
Mergers and Acquisitions
Development of Innovative Products/Novel Product Launches
Agreements, Collaborations and Partnerships

9 Company Profiles
3M PHARMACEUTICALS, INC.
Company Overview
Product Information
Development and Strategies
Financials
ASTRAZENECA PLC
Company Overview
Development and Strategies
Financials
BOEHRINGER INGELHEIM GMBH
Company Overview
Product Information
Development and Strategies
Financials
CIPLA, INC.
Company Overview
Product Information
Development and Strategies
Financials
DR. REDDY'S LABORATORIES LTD.
Company Overview
Product Information
Financials
GLAXOSMITHKLINE PLC
Company Overview
Product Information
Development and Strategies
Financials
KONINKLIJKE PHILIPS N.V. (RESPIRONICS, INC.)
Company Overview
Product Information
LUPIN, LIMITED
Company Overview
Development and Strategies
Financials
MYLAN N.V.
Company Overview
Product Information
Development and Strategies
Financials
NOVARTIS AG
Company Overview
Product Information
Development and Strategies
Financials
OMRON CORPORATION
Company Overview
Product Information
Development and Strategies
Financials
PFIZER, INC.
Company Overview
Product Information
Financials
PULMATRIX, INC.
Company Overview
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Company Overview
Product Information
Development and Strategies
Financials
VECTURA GROUP PLC
Company Overview
Product Information
Development and Strategies
Financials

10 Appendix
Acronyms

List of Tables
Summary Table A: Global Market for Pulmonary Drug Delivery Systems, by Delivery SystemType, Tthrough 2022
Summary Table B: Global Market for Pulmonary Drug Delivery Systems, by Region Tthrough 2022
Table 1: Global Asthma and COPD Snapshot, 1990-2015
Table 2: Key Products Going off-Patent, 2016-2021
Table 3: Inhaler Device Characteristics Snapshot
Table 4: Global Market for Pulmonary Drug, Delivery Systems by Delivery System Tthrough 2022
Table 5: Global Respiratory Product Sales, 2014-2016
Table 6: Capsule Based Inhaler Devices
Table 7: Blister Based Inhaler Devices
Table 8: Reservoir/Cartridge Based Inhaler Devices
Table 9: Global Dry Powder Inhaler Market, by Region, Through 2022
Table 10: MDIs, HFA Propellant
Table 11: MDIs, Anti-Inflammatory Medicine
Table 12: MDIs, Combination Medicine
Table 13: Commonly Used MDIs
Table 14: Global MDI Market, by Region, Through 2022
Table 15: Comparison of Nebulizers
Table 16: Marketed Nebulizers by Manufacturer
Table 17: Global Nebulizer Market, by Region, Through 2022
Table 18: Inhaled Steroids
Table 19: Inhaled Corticosteroids
Table 20: Inhaled Corticosteroids, Combination Inhalers
Table 21: Short-Acting Inhaled Beta-Agonist Bronchodilators
Table 22: Short-Acting Inhaled Muscarinic Antagonist Combination Bronchodilators
Table 23: Long-Acting Inhaled LABAs (Long-Acting Beta2 Agonists)
Table 24: Long-Acting Inhaled LAMAs (Long-Acting Muscarinic Antagonists)
Table 25: LABA and LAMA Combinations
Table 26: Top Asthma/COPD Product Sales, 2015-2017
Table 27: U.S. Asthma Mortality, 2015
Table 28: U.S. Asthma Prevalence, 2015
Table 29: Global Asthma Market, by Region Through 2022
Table 30: Global COPD Market, by Region, Through 2022
Table 31: Global Market for Other Pulmonary Diseases, by Region, Through 2022
Table 32: Canadian Disease Prevalence, Asthma and COPD, 2012-2014
Table 33: European Self-Reported Asthma, 2014
Table 34: European Self-Reported COPD, 2014
Table 35: Leading Causes of Death in Australia, 2011-2016
Table 36: Patent Review, Inhaler
Table 37: Sunovion Pharmaceuticals, Inc., SUN-101/ eFlow (Glycopyrrolate), 2017
Table 38: AstraZeneca plc, (Pearl Therapeutics), Pulmonary Products Pipeline
Table 39: Teva Pharmaceuticals Industries Ltd., Pulmonary Products Pipeline
Table 40: Vectura Group plc, Pulmonary Products Pipeline
Table 41: GlaxoSmithKline plc, Pulmonary Products Pipeline
Table 42: 3M Pharmaceuticals, Inc., Marketed Products, 2016
Table 43: 3M Pharmaceuticals, Inc., Net Revenue, 2015-2017
Table 44: AstraZeneca plc, Marketed Products, 2016
Table 45: AstraZeneca plc., Key Developments, 2016
Table 46: AstraZeneca plc, Net Revenue, 2014-2016
Table 47: Boehringer Ingelheim GmbH, Marketed Product, 2016
Table 48: Boehringer Ingelheim GmbH, Net Revenue, 2014-2016
Table 49: Cipla, Inc., Marketed Products, 2016
Table 50: Cipla, Inc., Net Revenue, 2015-2017
Table 51: Dr. Reddy’s Laboratories Ltd., Marketed Products, 2016
Table 52: Dr. Reddy’s Laboratories Ltd., Net Revenue, 2015-2017
Table 53: GlaxoSmithKline plc, Marketed Products, 2016
Table 54: GlaxoSmithKline plc, Net Revenue, 2014-2016
Table 55: Koninklijke Philips N.V., Marketed Products, 2016
Table 56: Lupin Limited, Key Developments
Table 57: Lupin Limited, Net Revenue, 2015-2017
Table 58: Mylan N.V., Marketed Products, 2016
Table 59: Mylan N.V., Key Developments, 2016
Table 60: Mylan N.V., Net Revenue, 2015-2017
Table 61: Novartis AG, Marketed Products, 2016
Table 62: Novartis AG, Key Developments, 2016
Table 63: Novartis AG, Net Revenue, 2014-2016
Table 64: Omron Corp., Marketed Products, 2016
Table 65: Omron Corp., Net Revenue, 2014-2016
Table 66: Pfizer, Inc., Marketed Products, 2016
Table 67: Pfizer, Inc., Net Revenue, 2014-2016
Table 68: Teva Pharmaceutical Industries Ltd., Marketed Products, 2016
Table 69: Teva Pharmaceutical Industries Ltd., Net Revenue, 2014-2016
Table 70: Vectura Group plc, Marketed Products, 2016
Table 71: Vectura Group plc, Net Revenue, 2015-2017
Table 72: Abbreviations Used in Pulmonary Drug Delivery Systems

List of Figures
Summary Figure A: Global Market for Pulmonary Drug Delivery Systems, by Delivery SystemType, 2016-2022
Summary Figure B: Global Market for Pulmonary Drug Delivery Systems, by Region, 2016-2022
Figure 1: Regional Estimation of Daily Smoking Patterns, 2015
Figure 2: Global Market for Pulmonary Drug, Delivery Systems by Delivery System, 2016-2022
Figure 3: Global Dry Powder Inhaler Market by Region, 2016-2022
Figure 4: Global MDI Market, by Region, 2016--2022
Figure 5: Global Nebulizer Market, by Region, 2016-2022
Figure 6: Non-communicable Disease Mortality Share, by Cause of Death, 2015
Figure 7: Global Asthma Market, 2016-2022
Figure 8: Global Asthma Market by Region, 2016-2022
Figure 9: Top 10 Leading Causes of Death in the World, 2015
Figure 10: Global COPD Market, 2016-2022
Figure 11: Global COPD Market, by Region, 2016-2022
Figure 12: Global Market for Other Pulmonary Disease, 2016-2022
Figure 13: Global Market for Other Pulmonary Disease, by Region, 2016-2022
Figure 14: North American Pulmonary Drug Delivery Systems Market, 2016-2022
Figure 15: Impact of Asthma in North America, Annual Mortality Rate (Per 100,000 People), 2016
Figure 16: Impact of COPD in North America, Annual Mortality Rate (Per 100,000 People), 2016
Figure 17: Mexican Population Health Issues, Proportional Mortality, 2014
Figure 18: Impact of Asthma in Europe, Annual Mortality Rate (Per 100,000 People), 2016
Figure 19: Impact of COPD in Europe, Annual Mortality Rate (Per 100,000 People), 2016
Figure 20: European Pulmonary Drug Delivery Systems Market, 2016-2022
Figure 21: United Kingdom Mortality Rates in Males, 2015
Figure 22: United Kingdom Mortality Rate in Females, 2015
Figure 23: Leading Causes of Death in Italy in Percent Change, 2005-2016
Figure 24: Spain Mortality Rate in Women, 2014
Figure 25: Spain Mortality Rate in Men, 2014
Figure 26: Leading Causes of Death in Europe, 2015
Figure 27: Asia Pacific Pulmonary Drug Delivery Systems Market, 2016-2022
Figure 28: Impact of Asthma in Asia, Annual Mortality Rate (Per 100,000 People), 2016
Figure 29: Impact of COPD in Asia, Annual Mortality Rate (Per 100,000 People), 2016
Figure 30: Impact of Asthma in Middle East and Africa, Annual Mortality Rate (Per 100,000 People), 2016
Figure 31: Impact of COPD in Middle East and Africa, Annual Mortality Rate (Per 100,000 People), 2016
Figure 32: Middle East and African Pulmonary Drug Delivery Systems Market, 2016-2022
Figure 33: Impact of Asthma in South America, Annual Mortality Rate (Per 100,000 People), 2016
Figure 34: Impact of COPD in South America, Annual Mortality Rate (Per 100,000 People), 2016
Figure 35: Impact of COPD in South America, Annual Mortality Rate (Per 100,000 People), 2016
Figure 36: South American Pulmonary Drug Delivery Systems Market, 2016-2022
Figure 37: 3M Pharmaceuticals, Inc. Revenue Share by Region, 2016
Figure 38: 3M Pharmaceuticals, Inc. Revenue Share by Business Segment, 2016
Figure 39: AstraZeneca Plc. Revenue Share by Region, 2016
Figure 40: AstraZeneca Plc. Revenue Share by Business Segment, 2016
Figure 41: Boehringer Ingelheim GmbH Research and Development Expenditure, 2014-2016
Figure 42: Boehringer Ingelheim GmbH Revenue Share by Region, 2016
Figure 43: Boehringer Ingelheim GmbH Revenue Share by Business Segment, 2016
Figure 44: Cipla, Inc. Research and Development Expenditure, 2014-2017
Figure 45: Cipla, Inc. Revenue Share by Region, 2017
Figure 46: Cipla, Inc. Revenue Share by Business Segment, 2017
Figure 47: Dr. Reddy’s Laboratories, Ltd. Revenue Share by Region, 2017
Figure 48: Dr. Reddy’s Laboratories, Ltd. Revenue Share by Business Segment, 2017
Figure 49: GlaxoSmithKline, Plc. Pharmaceuticals Revenue Share by Therapy Areas, 2016
Figure 50: GlaxoSmithKline, Plc. Revenue Share by Region, 2016
Figure 51: Mylan N.V., Revenue Share by Therapy Areas, 2016
Figure 52: Mylan N.V. Revenue Share by Region, 2016
Figure 53: Novartis AG Revenue Share, by Region, 2016
Figure 54: Novartis AG Revenue Share by, Business Segment, 2016
Figure 55: Omron Corporation Revenue Share, by Healthcare Business Segment (HCB), 2017
Figure 56: Omron Corporation Revenue Share, by Region, 2017
Figure 57: Pfizer, Inc Revenue Share, by Region, 2016
Figure 58: Pfizer, Inc. Revenue Share, by Business Segment, 2016
Figure 59: Teva Pharmaceutical Industries, Ltd Revenue Share, by Region, 2017
Figure 60: Teva Pharmaceutical Industries, Ltd Revenue Share, by Business Segment, 2016
Figure 61: Vectura Group plc, Research and Development Expenditure, 2014-2016
Figure 62: Vectura Group PLC. Revenue Share, bBy Region, 2017
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • 3M Pharmaceuticals, Inc.
  • Boehringer Ingelheim Gmbh
  • Glaxosmithkline Plc
  • Mylan N.V.
  • Omron Corporation
  • Pulmatrix, Inc.
  • MORE
Summary:

Pulmonary drug delivery is an alternative to oral drug delivery. Pulmonary drug delivery is primarily advantageous for the treatment of respiratory diseases due to systemic administration via fast absorption by the alveolar region. The pulmonary drug delivery method depends on the development of simple, cost effective and easy to use devices. These devices are designed to facilitate consistent drug delivery with increased lung penetration and multi-dosage facilities. Currently, manufacturers are concentrating on the development of small, portable devices that encourage higher patient compliance. The World Health Organization (WHO) estimates that there were approximately 251 million people suffering from COPD globally in 2016. It is estimated by the WHO that nearly 3.17 million deaths occurred in 2015 due to the disease itself. The primary cause of the disease is smoking tobacco. The growing number of smokers in developing economies is increasing the incidence of the disease.

The market for pulmonary drug delivery systems is witnessing growth due to the rising prevalence of respiratory disorders such as asthma, COPD and other chronic illnesses. Other factors that are driving the growth of the market are the emergence of novel inhaler designs and increased use of non-invasive drug delivery methods.
Note: Product cover images may vary from those shown
5 of 6
3M Pharmaceuticals, Inc.
Astrazeneca Plc
Boehringer Ingelheim Gmbh
Cipla, Inc.
Dr. Reddy's Laboratories Ltd.
Glaxosmithkline Plc
Koninklijke Philips N.V. (Respironics, Inc.)
Lupin, Limited
Mylan N.V.
Novartis Ag
Omron Corporation
Pfizer, Inc.
Pulmatrix, Inc.
Teva Pharmaceutical Industries, Ltd.
Vectura Group Plc
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll